Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | HPD | P32754 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.36 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750711 | 1.00 | NR4A2 (0.47) | NR4A2NR4A1NR4A3GPR132SMPD1 | |
| SCHEMBL3750716 | 1.00 | NR4A2 (0.47) | NR4A2NR4A1NR4A3GPR132SMPD1 | |
| SCHEMBL3739931 | 0.91 | SMPD1 (0.40) | NR4A2NR4A1NR4A3GPR132SMPD1 | |
| SCHEMBL3739936 | 0.91 | SMPD1 (0.40) | NR4A2NR4A1NR4A3GPR132SMPD1 | |
| SCHEMBL3739926 | 0.91 | SMPD1 (0.40) | NR4A2NR4A1NR4A3GPR132SMPD1 | |
| SCHEMBL3749384 | 0.86 | DPP4 (0.39) | — | |
| SCHEMBL3749382 | 0.86 | DPP4 (0.39) | — | |
| SCHEMBL3749376 | 0.86 | DPP4 (0.39) | — | |
| SCHEMBL3751685 | 0.84 | CYP11B1 (0.38) | — | |
| SCHEMBL3751690 | 0.84 | CYP11B1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | claimed |
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | NR4A2 3032/4885NR4A1 2049/4885NR4A3 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.